Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHV NYSE:EBS NASDAQ:VSTM NASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$3.09+1.5%$2.74$1.84▼$5.31$157.64M1.53638,744 shs156,943 shsEBSEmergent Biosolutions$7.88-1.6%$7.73$4.02▼$12.73$420.13M2.031.22 million shs122,481 shsVSTMVerastem$9.79-0.4%$7.36$2.54▼$11.24$598.48M0.921.87 million shs582,341 shsXOMAXOMA Royalty$37.15-1.9%$30.13$18.35▼$38.34$448.15M0.9844,822 shs11,988 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences-1.30%+3.75%+19.22%+2.01%-32.89%EBSEmergent Biosolutions-2.09%+5.19%-9.83%+27.99%+1.40%VSTMVerastem+1.03%-4.01%+19.46%+84.93%+249.47%XOMAXOMA Royalty+1.18%+7.10%+20.69%+58.21%+30.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$3.09+1.5%$2.74$1.84▼$5.31$157.64M1.53638,744 shs156,943 shsEBSEmergent Biosolutions$7.88-1.6%$7.73$4.02▼$12.73$420.13M2.031.22 million shs122,481 shsVSTMVerastem$9.79-0.4%$7.36$2.54▼$11.24$598.48M0.921.87 million shs582,341 shsXOMAXOMA Royalty$37.15-1.9%$30.13$18.35▼$38.34$448.15M0.9844,822 shs11,988 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences-1.30%+3.75%+19.22%+2.01%-32.89%EBSEmergent Biosolutions-2.09%+5.19%-9.83%+27.99%+1.40%VSTMVerastem+1.03%-4.01%+19.46%+84.93%+249.47%XOMAXOMA Royalty+1.18%+7.10%+20.69%+58.21%+30.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHVAchieve Life Sciences 3.50Strong Buy$14.67375.42% UpsideEBSEmergent Biosolutions 3.00Buy$13.5071.43% UpsideVSTMVerastem 3.00Buy$13.2935.78% UpsideXOMAXOMA Royalty 3.33Buy$69.5087.08% UpsideCurrent Analyst Ratings BreakdownLatest ACHV, VSTM, XOMA, and EBS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025XOMAXOMA RoyaltyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/9/2025VSTMVerastemBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.009/3/2025EBSEmergent BiosolutionsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.008/25/2025VSTMVerastemB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/21/2025ACHVAchieve Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.008/12/2025VSTMVerastemZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/12/2025XOMAXOMA RoyaltyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/8/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $13.006/25/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHVAchieve Life SciencesN/AN/AN/AN/A$0.61 per shareN/AEBSEmergent Biosolutions$1.04B0.40$1.86 per share4.24$8.91 per share0.88VSTMVerastem$10K60,216.89N/AN/A($0.65) per share-15.05XOMAXOMA Royalty$28.49M15.76N/AN/A$6.95 per share5.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHVAchieve Life Sciences-$39.83M-$1.46N/AN/AN/AN/A-193.49%-116.68%11/6/2025 (Estimated)EBSEmergent Biosolutions-$190.60M$2.453.213.80N/A16.38%24.63%8.97%11/5/2025 (Estimated)VSTMVerastem-$130.64M-$3.28N/AN/AN/AN/A-2,003.62%-119.85%11/5/2025 (Estimated)XOMAXOMA Royalty-$13.82M-$1.55N/AN/AN/A-27.57%2.63%0.97%11/6/2025 (Estimated)Latest ACHV, VSTM, XOMA, and EBS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025XOMAXOMA Royalty-$0.12$0.48+$0.60$0.44$9.39 million$13.13 million8/7/2025Q2 2025ACHVAchieve Life Sciences-$0.37-$0.37N/A-$0.37N/AN/A8/7/2025Q2 2025VSTMVerastem-$0.64-$0.39+$0.25-$0.39$6.01 million$2.14 million8/6/2025Q2 2025EBSEmergent Biosolutions-$0.26$0.16+$0.42-$0.22$148.55 million$140.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHVAchieve Life SciencesN/AN/AN/AN/AN/AEBSEmergent BiosolutionsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHVAchieve Life Sciences0.216.646.64EBSEmergent Biosolutions1.255.663.00VSTMVerastem2.063.463.44XOMAXOMA Royalty1.414.884.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHVAchieve Life Sciences33.52%EBSEmergent Biosolutions78.40%VSTMVerastem88.37%XOMAXOMA Royalty95.92%Insider OwnershipCompanyInsider OwnershipACHVAchieve Life Sciences3.00%EBSEmergent Biosolutions3.20%VSTMVerastem2.10%XOMAXOMA Royalty7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHVAchieve Life Sciences2051.10 million49.57 millionOptionableEBSEmergent Biosolutions2,42053.35 million51.64 millionOptionableVSTMVerastem5061.54 million60.25 millionOptionableXOMAXOMA Royalty1012.09 million11.22 millionOptionableACHV, VSTM, XOMA, and EBS HeadlinesRecent News About These CompaniesXOMA Royalty (NASDAQ:XOMA) Upgraded to Strong-Buy at Zacks ResearchSeptember 14 at 6:22 AM | marketbeat.comThe Pharma Letter M&A roundup - August 2025September 9, 2025 | thepharmaletter.comTNuveen LLC Invests $286,000 in XOMA Royalty Corporation $XOMASeptember 8, 2025 | marketbeat.comXOMA Royalty Corporation $XOMA Shares Sold by BVF Inc. ILSeptember 5, 2025 | marketbeat.comWall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should KnowSeptember 3, 2025 | zacks.comXOMA Royalty Corporation Executives to Present Company Update at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | quiverquant.comQXOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comHere's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock NowSeptember 1, 2025 | zacks.comQ3 EPS Estimates for XOMA Royalty Lifted by HC WainwrightAugust 26, 2025 | marketbeat.comHC Wainwright Predicts Stronger Earnings for XOMA RoyaltyAugust 24, 2025 | marketbeat.comXoma’s Strategic Acquisitions and Innovative Financial Strategies Drive Buy RatingAugust 22, 2025 | tipranks.comMural Oncology and XOMA Royalty Corporation Announce Definitive Agreement for Acquisition of Mural OncologyAugust 20, 2025 | quiverquant.comQMural Oncology to be acquired by XOMA unit for up to $2.24/share in cashAugust 20, 2025 | seekingalpha.comMural Oncology Enters Definitive Agreement for Acquisition by XOMA Royalty Corporation in Cash Deal Valued at Approximately $36.2 MillionAugust 20, 2025 | quiverquant.comQMural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per ShareAugust 20, 2025 | globenewswire.comQ3 EPS Estimates for XOMA Royalty Reduced by Leerink PartnrsAugust 19, 2025 | marketbeat.comHow Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%August 18, 2025 | zacks.comLeerink Partnrs Raises Earnings Estimates for XOMA RoyaltyAugust 17, 2025 | marketbeat.comXOMA Royalty (NASDAQ:XOMA) Rating Increased to Hold at Zacks ResearchAugust 17, 2025 | marketbeat.comXOMA Royalty (NASDAQ:XOMA) Releases Earnings Results, Beats Estimates By $0.60 EPSAugust 16, 2025 | marketbeat.comXOMA Royalty Corporation Beat Analyst Profit Forecasts, And Analysts Have New EstimatesAugust 16, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACHV, VSTM, XOMA, and EBS Company DescriptionsAchieve Life Sciences NASDAQ:ACHV$3.08 +0.05 (+1.48%) As of 11:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.Emergent Biosolutions NYSE:EBS$7.88 -0.13 (-1.56%) As of 11:20 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Verastem NASDAQ:VSTM$9.78 -0.04 (-0.36%) As of 11:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.XOMA Royalty NASDAQ:XOMA$37.15 -0.71 (-1.88%) As of 11:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
